Showing results (1-10 of 13) with videos related to
Sort By:
Pageof 2
Hematology/Oncology Clinics of North America|August 30, 2001
Clinical conduct and nursing quality of life in prostate cancerV J Sinibaldi, R Z ArzoomanianSeminars in Oncology|December 22, 1999
Preliminary evaluation of a short course of estramustine phosphate and docetaxel (Taxotere) in the treatment of hormone-refractory prostate cancerV J Sinibaldi, M Carducci, M Laufer, et al.American Journal of Ophthalmology|March 1, 1996
Ocular symptoms and signs associated with suramin sodium treatment for metastatic cancer of the prostateR K Hemady, V J Sinibaldi, M A EisenbergerUrology|February 7, 2001
Rapid disease progression after the administration of bicalutamide in patients with metastatic prostate cancerM Laufer, V J Sinibaldi, M A Carducci, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 1, 1995
Evaluation of prostate-specific antigen as a surrogate marker for response of hormone-refractory prostate cancer to suramin therapyR Sridhara, M A Eisenberger, V J Sinibaldi, et al.The Journal of Urology|June 7, 2000
Complete androgen blockade for prostate cancer: what went wrong?M Laufer, S R Denmeade, V J Sinibaldi, et al.Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|July 29, 1998
Evaluation of biomarkers of survival response in hormone-refractory prostate cancer patients treated with suraminR Sridhara, M A Eisenberger, V J Sinibaldi, et al.Cancer Chemotherapy and Pharmacology|January 1, 1988
Salivary concentrations of hexamethylene bisacetamide (HMBA) in patients receiving 5-day continuous infusionsB A Conley, M J Egorin, E G Zuhowski, et al.Brain : a Journal of Neurology|December 1, 1996
A prospective study of suramin-induced peripheral neuropathyV Chaudhry, M A Eisenberger, V J Sinibaldi, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 1, 1995
Development and validation of a pharmacokinetically based fixed dosing scheme for suraminL M Reyno, M J Egorin, M A Eisenberger, et al.Pageof 2